...
首页> 外文期刊>Circulation. Cardiovascular quality and outcomes >The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina.
【24h】

The cost-effectiveness of percutaneous coronary intervention as a function of angina severity in patients with stable angina.

机译:稳定型心绞痛患者经皮冠状动脉介入治疗的成本效益与心绞痛严重程度的关系。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: The COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial compared percutaneous coronary intervention (PCI) plus optimal medical therapy (OMT) to OMT alone in reducing the risk of cardiovascular events in 2287 patients with stable coronary disease. We examined the cost-effectiveness of PCI as a function of angina severity at the time of randomization. METHODS AND RESULTS: Angina severity was assessed with the Seattle Angina Questionnaire (SAQ). Patients were grouped into tertiles based on the distribution of baseline scores such that higher tertiles represented better health status. Clinically significant improvement from baseline within individual patients was defined as score increases of >8 for physical limitation, >20 for angina frequency, and >16 for quality-of-life domains. The incremental cost-effectiveness ratio for PCI was calculated as the difference in costs divided by the difference in proportion of patients with clinically significant improvement. Improvement in angina severity was significantly greater for PCI patients in the lowest and middle tertiles. The number of patients needed to treat was much larger for the highest tertile. The added in-trial cost of PCI ranged from Dollars 7300 to Dollars 13 000. Incremental cost-effectiveness ratios ranged from Dollars 80 000 to Dollars 330 000 for the lowest and middle tertiles and from Dollars 520 000 to >Dollars 3 million for the highest tertile for 1 additional patient to achieve significant clinical improvement in health status. CONCLUSIONS: The incremental cost of PCI to provide meaningful clinical benefit above that achieved by OMT alone was lower for patients with severe angina than for those with mild or no angina. However, it is uncertain that at any level of angina severity that PCI as an initial strategy would achieve a socially acceptable cost threshold. Clinical Trial Registration- URL: http://www.clinicaltrials.gov. Unique identifier: NCT00007657.
机译:背景:COURAGE(利用血运重建和积极药物评估的临床结果)试验比较了单独的经皮冠状动脉介入治疗(PCI)加上最佳药物治疗(OMT)与OMT相比,在2287例稳定型冠心病患者中降低了发生心血管事件的风险。我们在随机化时检查了PCI的成本效益与心绞痛严重程度的关系。方法和结果:用西雅图心绞痛问卷(SAQ)评估心绞痛的严重程度。根据基线评分的分布将患者分为三分位数,以便三分位数越高代表健康状况越好。个体患者相对于基线的临床显着改善定义为:身体限制得分增加> 8,心绞痛频率得分增加> 20,生活质量域得分增加> 16。 PCI的成本效益比增量计算为成本差异除以具有临床显着改善的患者比例差异。对于最低和中等三分位数的PCI患者,心绞痛严重程度的改善明显更大。对于最高三分位数,需要治疗的患者数量要大得多。 PCI的附加试用成本从7300美元到13000美元不等。最低和中等三分位数的增量成本效益比从80000美元到330000美元,最高的从520000美元到> 300万美元不等。三分位数可增加1位患者的健康状况。结论:重度心绞痛患者的PCI增加成本以提供有意义的临床收益,高于单纯OMT所获得的收益要低于轻度或无心绞痛患者。但是,不确定在任何程度的心绞痛中,PCI作为初始策略能否达到社会可接受的成本阈值。临床试验注册-URL:http://www.clinicaltrials.gov。唯一标识符:NCT00007657。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号